Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2019 1
2020 1
2022 3
2023 8
2024 8
2025 14

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

31 results

Results by year

Filters applied: . Clear all
Page 1
Neoadjuvant FOLFIRINOX versus neoadjuvant gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer (PREOPANC-2): a multicentre, open-label, phase 3 randomised trial.
Janssen QP, van Dam JL, van Bekkum ML, Bonsing BA, Bos H, Bosscha KP, Bouwense SAW, Brouwer-Hol L, Bruynzeel AME, Busch OR, Coene PLO, van Eijck CHJ, de Groot JWB, Haberkorn BCM, de Hingh IHJT, Karsten TM, Kazemier G, van der Kolk MB, Liem MSL, Loosveld OJL, Luelmo SAC, Luyer MDP, Mekenkamp LJM, Mieog JSD, Nieuwenhuijs VB, Nuyttens JJME, Patijn GA, van Santvoort HC, Stommel MWJ, Versteijne E, de Vos-Geelen J, de Wilde RF, Zonderhuis BM, van der Holt B, Homs MYV, van Tienhoven G, Besselink MG, Wilmink JW, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Janssen QP, et al. Lancet Oncol. 2025 Oct;26(10):1346-1356. doi: 10.1016/S1470-2045(25)00363-8. Epub 2025 Sep 10. Lancet Oncol. 2025. PMID: 40945523 Clinical Trial.
Perioperative or adjuvant mFOLFIRINOX for resectable pancreatic cancer (PREOPANC-3): study protocol for a multicenter randomized controlled trial.
van Dam JL, Verkolf EMM, Dekker EN, Bonsing BA, Bratlie SO, Brosens LAA, Busch OR, van Driel LMJW, van Eijck CHJ, Feshtali S, Ghorbani P, de Groot DJA, de Groot JWB, Haberkorn BCM, de Hingh IH, van der Holt B, Karsten TM, van der Kolk MB, Labori KJ, Liem MSL, Loosveld OJL, Molenaar IQ, Polée MB, van Santvoort HC, de Vos-Geelen J, Wumkes ML, van Tienhoven G, Homs MYV, Besselink MG, Wilmink JW, Groot Koerkamp B; Dutch Pancreatic Cancer Group. van Dam JL, et al. Among authors: dekker en. BMC Cancer. 2023 Aug 7;23(1):728. doi: 10.1186/s12885-023-11141-5. BMC Cancer. 2023. PMID: 37550634 Free PMC article.
Surgical Complications in Patients with (borderline) Resectable Pancreatic Cancer after Neoadjuvant Therapy in the PREOPANC-2 Randomized Controlled Trial.
Dekker EN, Theijse RT, van Dam JL, Janssen QP, Stoop TF, Bonsing BA, Bosscha KP, Bouwense SAW, Busch OR, Coene PLO, van Eijck CHJ, van Her Harst E, de Hingh IHJT, Karsten TM, Kazemier G, van der Kolk MB, Liem MSL, Mieog JSD, Nieuwenhuijs VB, Patijn GA, van Santvoort HC, Schreinemakers JMJ, de Wilde RF, Wit F, Zonderhuis BM, Homs MYV, van Tienhoven G, Wilmink JW, Besselink MG, Koerkamp BG; Dutch Pancreatic Cancer Group. Dekker EN, et al. Ann Surg. 2025 Aug 12. doi: 10.1097/SLA.0000000000006910. Online ahead of print. Ann Surg. 2025. PMID: 40792645
Carbohydrate antigen 19-9 (CA19-9) response after induction FOLFIRINOX for locally advanced pancreatic cancer identifies patients who may benefit from surgical exploration: multicentre, observational cohort study.
Dekker EN, van Klaveren D, Verkolf EMM, de Wilde RF, Besselink MG, O'Reilly EM, Paniccia A, Katz MHG, Tzeng CD, Wei AC, Zureikat AH, Groot Koerkamp B; Trans-Atlantic Pancreatic Surgery (TAPS) Consortium. Dekker EN, et al. Br J Surg. 2025 Feb 1;112(2):znaf011. doi: 10.1093/bjs/znaf011. Br J Surg. 2025. PMID: 39967445 Free PMC article.
Risk of lymph node metastasis in pT2 rectal cancer: a nationwide retrospective analysis.
Albers SC, Geitenbeek RTJ, van Geffen EGM, Sluckin TC, Hazen SJA, Kusters M, Tanis PJ, Consten ECJ, Dekker E, Bastiaansen BAJ, Wiggers JK, Hompes R; Dutch Snapshot Research Group and MIRECA (Taskforce for Minimally Invasive Rectal Carcinoma surgery). Albers SC, et al. Br J Surg. 2025 Feb 1;112(2):znaf028. doi: 10.1093/bjs/znaf028. Br J Surg. 2025. PMID: 39982377 No abstract available.
Blood Sample Collection in Randomized Controlled Trials for Biomarker Discovery and Validation: Experience of the PREOPANC-2 Trial.
Dekker EN, Janssen QP, van Dam JL, Strijk GJ, Verkolf EMM, Kandala S, Dumas J, Fellah A, O'Reilly EM, Besselink MG, van Eijck CHJ, Homs MYV, van Tienhoven GJ, Wilmink JW, Mustafa DAM, Groot Koerkamp B; Dutch Pancreatic Cancer Group. Dekker EN, et al. Ann Surg Oncol. 2025 Jul;32(7):5092-5101. doi: 10.1245/s10434-025-16890-0. Epub 2025 Feb 5. Ann Surg Oncol. 2025. PMID: 39907876 Free PMC article. Clinical Trial.
Nationwide Outcome of Tailored Surgery for Symptomatic Chronic Pancreatitis Based on Pancreatic Morphology: Validation of the International Guidelines.
Van Veldhuisen CL, Leseman CA, De Rijk FEM, Dekker EN, Wellens MJ, Michiels N, Stommel MWJ, Krikke C, Hofker HS, Mieog JSD, Bouwense SA, Van Eijck CH, Groot Koerkamp B, Haen R, Boermeester MA, Busch OR, Van Santvoort HC, Besselink MG; Dutch Pancreatitis Study Group. Van Veldhuisen CL, et al. Among authors: dekker en. Ann Surg. 2025 Apr 1;281(4):655-663. doi: 10.1097/SLA.0000000000006176. Epub 2023 Dec 13. Ann Surg. 2025. PMID: 38088187 Free PMC article.
Salvageable locoregional recurrence and stoma rate after local excision of pT1-2 rectal cancer - A nationwide cross-sectional cohort study.
Moolenaar LR, van Geffen EGM, Hazen SJA, Sluckin TC, Beets GL, Leijtens JWA, Talsma AK, de Wilt JHW, Tanis PJ, Kusters M, Hompes R, Tuynman JB; Dutch Snapshot Research Group; Collaborators Snapshot Registry. Moolenaar LR, et al. Eur J Surg Oncol. 2025 Jun;51(6):109623. doi: 10.1016/j.ejso.2025.109623. Epub 2025 Jan 23. Eur J Surg Oncol. 2025. PMID: 40009914 Free article.
31 results